Business ❯ Pharmaceutical Industry ❯ Market Dynamics ❯ Sales Forecasting

Revenue Targets

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

Regulators limited the relaunch to one regimen because safety concerns offset strong efficacy data.